贝达喹啉在耐多药肺结核患者中的应用效果

Application Effect of Bedaquiline in Patients with Multidrug-resistant Pulmonary Tuberculosis

目的:分析贝达喹啉在耐多药肺结核(MDR-TB)患者中的应用效果。方法:选取2022年1月—2023年6月茂名市慢性病防治中心收治的60例MDR-TB患者。根据随机数表法将其分为对照组与观察组,各30例。对照组采用个体化抗结核药物治疗,观察组在对照组基础上采用贝达喹啉。比较两组临床疗效,相关指标,治疗前后生活质量及不良反应。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。观察组痰菌转阴率、病灶吸收有效率均高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组生理功能、生活活力、身体疼痛、总体健康状况评分均高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:针对MDR-TB患者增加贝达喹啉治疗,能够更好地改善患者疾病症状,提高痰菌转阴率,提高患者生活质量。

Objective:To analyze application effect of Bedaquiline in patients with multidrug-resistant pulmonary tuberculosis(MDR-TB).Method:A total of 60 MDR-TB patients admitted to Maoming Chronic Disease Prevention and Control Center from January 2022 to June 2023 were selected.They were divided into control group and observation group according to random number table method,with 30 cases in each group.The control group was treated with individualized antituberculosis drugs,and the observation group was treated with Bedaquiline on the basis of the control group.The clinical efficacy,related indexes,quality of life before and after treatment and adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The negative conversion rate of sputum and the effective rate of lesion absorption in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the scores of physiological function,vitality,body pain and general health status of the observation group were higher than those of the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The addition of Bedaquiline therapy for MDR-TB patients can better improve the disease symptoms,increase the sputum negative conversion rate,and improve the quality of life of patients.